{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:00:06Z","timestamp":1780639206971,"version":"3.54.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200180"],"award-info":[{"award-number":["82200180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The With-No-Lysine (WNK) kinase family plays critical roles in cellular signaling, yet its significance in acute myeloid leukemia (AML) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed public databases and primary patient samples for WNK family expression. CRISPR dependency scores were used to assess gene essentiality. The effects of pharmacological WNK1 inhibition (using WNK463 and WNK11) were evaluated on AML cell lines, primary blasts, and mouse xenograft models. Apoptosis was assessed via pro-apoptotic protein expression (Bim, Puma). Transcriptomic analysis identified downstream pathways, and combination studies with venetoclax were performed\n                      <jats:italic>in vitro<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      WNK1, but not other WNK family members, was highly expressed in AML, particularly in adverse subtypes such as FLT3-ITD mutated AML. CRISPR screening confirmed WNK1 as essential for AML cell survival. Pharmacological inhibition of WNK1 suppressed proliferation of AML cells and primary blasts, induced apoptosis through upregulation of Bim and Puma, and impeded tumor growth in xenograft models without significant toxicity. Transcriptomic analysis revealed that WNK1 inhibition downregulated DNA replication pathway genes (MCM5, CHAF1B, GINS2), whose high expression correlates with poor prognosis. Elevated WNK1 expression was associated with resistance to venetoclax. Combining WNK463 with venetoclax produced synergistic anti-leukemic effects\n                      <jats:italic>in vitro<\/jats:italic>\n                      , accompanied by enhanced Bim upregulation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study identifies WNK1 as a key oncogenic driver in AML and establishes WNK1 inhibition as a promising therapeutic strategy that not only suppresses AML progression but also sensitizes leukemia cells to venetoclax. These findings provide a rationale for novel combination regimens to overcome drug resistance in AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1828240","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:04:12Z","timestamp":1780635852000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting WNK1 suppresses acute myeloid leukemia progression and enhances sensitivity to venetoclax"],"prefix":"10.3389","volume":"16","author":[{"given":"Fangli","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Targeted Therapy and Clinical Translation, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Targeted Therapy and Clinical Translation, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Targeted Therapy and Clinical Translation, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Targeted Therapy and Clinical Translation, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Targeted Therapy and Clinical Translation, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Targeted Therapy and Clinical Translation, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Targeted Therapy and Clinical Translation, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]},{"name":"Laboratory of Targeted Therapy and Clinical Translation, Shanghai Institute of Hematology, Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"himony","year":"2025","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/9781118468678.ch9","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00640","article-title":"Outcomes of frontline triplet regimens with a hypomethylating agent, venetoclax, and isocitrate dehydrogenase inhibitor for intensive chemotherapy-ineligible patients with isocitrate dehydrogenase-mutated AML","volume":"43","author":"DiNardo","year":"2025","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184573","article-title":"Mechanisms of resistance to small molecules in acute myeloid leukemia","volume":"15","author":"Lang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/s41419-022-05249-y","article-title":"An update regarding the role of WNK kinases in cancer","volume":"13","author":"Xiu","year":"2022","journal-title":"Cell Death Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.01.007","article-title":"WNK kinase signaling in ion homeostasis and human disease","volume":"25","author":"Shekarabi","year":"2017","journal-title":"Cell Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1016\/j.cell.2022.09.042","article-title":"WNK kinases sense molecular crowding and rescue cell volume via phase separation","volume":"185","author":"Boyd-Shiwarski","year":"2022","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s42003-025-08551-5","article-title":"Kinase interaction analysis predicts actions of the WNK-OSR1\/SPAK pathway","volume":"8","author":"Taylor","year":"2025","journal-title":"Commun Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv4636","article-title":"NRBP1 pseudokinase binds to and activates the WNK pathway in response to osmotic stress","volume":"11","author":"Amnekar","year":"2025","journal-title":"Sci Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci188792","article-title":"Kidney-specific WNK1 amplifies kidney tubule responsiveness to potassium via WNK body condensates","volume":"135","author":"Boyd-Shiwarski","year":"2025","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/gr.217331.116","article-title":"Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia","volume":"27","author":"Wang","year":"2017","journal-title":"Genome Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114211","article-title":"Identification of WNK1 as a therapeutic target to suppress IgH\/MYC expression in multiple myeloma","volume":"43","author":"Ye","year":"2024","journal-title":"Cell Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4920","DOI":"10.1038\/s41467-025-59969-8","article-title":"WNK1 signalling regulates amino acid transport and mTORC1 activity to sustain acute myeloid leukaemia growth","volume":"16","author":"Duan","year":"2025","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41419-024-07027-4","article-title":"Single-cell sequencing analysis of multiple myeloma heterogeneity and identification of new theranostic targets","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s44318-025-00562-6","article-title":"MCM5 UFMylation regulates replication origin firing and fork progression","volume":"44","author":"Li","year":"2025","journal-title":"EMBO J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.669132","article-title":"MCM5 aggravates the HDAC1-mediated Malignant progression of lung cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41419-025-07392-8","article-title":"Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage","volume":"16","author":"Liu","year":"2025","journal-title":"Cell Death Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05891-w","article-title":"A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold","volume":"104","author":"Solana-Altabella","year":"2025","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1828240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:04:13Z","timestamp":1780635853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1828240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1828240"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1828240","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1828240"}}